United States Patent 10,772,880: Tradipitant Claims, Scope, Expiration, and Patent Landscape

U.S. Patent No. 10,772,880 protects dosing methods for tradipitant, an investigational neurokinin-1 receptor antagonist developed by Vanda Pharmaceuticals. The patent does not claim tradipitant as a chemical compound. Its claims focus on oral administration, immediate-release dosage forms, daily doses from 150 mg to 400 mg, and maintenance of specified plasma concentrations, including at least approximately 175 ng/mL.

The patent is commercially important if tradipitant reaches the market for any of the listed disorders. Its strongest practical coverage is directed to a tradipitant product administered at 85 mg twice daily or at another dose that produces sustained plasma concentrations of at least approximately 175 ng/mL. Because the patent claims methods of treatment rather than the product itself, infringement would generally require evidence that the accused product is intended, labeled, prescribed, or used for a claimed disease and dosing regimen.

What does U.S. Patent 10,772,880 cover?

U.S. Patent 10,772,880 covers methods of administering tradipitant to treat specified disorders while achieving defined daily doses or blood concentrations. The listed disorders are:

Pain
Behavioral stressors
Craving
Nausea
Vomiting
Substance dependence
Anxiety
Pruritus
Atopic dermatitis

The principal claim categories are:

Claim group	Core limitation	Commercial significance
Claims 1-3	Approximately 170 mg/day and plasma concentration of at least approximately 175 ng/mL	Protects a target-exposure regimen
Claims 4-8	Oral solid immediate-release tradipitant at 150-400 mg/day	Covers tablets and capsules across a broad dose range
Claims 9-13	Effective plasma concentration of at least 150, 175, 200, or 225 ng/mL	Creates concentration-based fallbacks and narrower claim tiers

Claim 1 is the principal concentration-based claim. It requires:

A patient requiring treatment;
A disease responsive to tradipitant;
Tradipitant therapy;
Approximately 170 mg/day; and
A plasma concentration of at least approximately 175 ng/mL during treatment.

Claims 2 and 3 narrow claim 1 by requiring oral administration or 85 mg twice daily.

Claim 4 is broader in dosage-form terms. It requires oral administration of tradipitant in a solid immediate-release form containing pharmaceutically acceptable excipients at a dose of 150 mg to 400 mg per day. Claims 5 through 8 narrow that coverage to capsules or tablets and specify once-daily or twice-daily regimens.

What are the independent claims in Patent 10,772,880?

Claims 1 and 4 are the independent claims.

Claim 1: exposure-targeted treatment method

Claim 1 is directed to a method of treating a listed disease by administering approximately 170 mg/day of tradipitant for the period needed to achieve and maintain a plasma concentration of at least approximately 175 ng/mL.

This claim combines a dose limitation with a pharmacokinetic result. The phrase "about 170 mg/day" provides a numerical dose boundary, while the plasma-concentration requirement adds an outcome that must be achieved and maintained during treatment.

The claim is not limited to one disease. It covers any of the listed conditions if the other limitations are satisfied. The claim also does not require a particular dosage form, although dependent claim 2 requires oral administration and dependent claim 3 specifies 85 mg twice daily.

Claim 4: oral immediate-release product and dose

Claim 4 requires:

An individual afflicted with one of the listed disorders;
Oral administration;
Tradipitant in a solid immediate-release form;
One or more pharmaceutically acceptable excipients; and
A daily dose of 150 mg to 400 mg.

This claim is potentially broader than claim 1 with respect to plasma concentration because it does not expressly require a minimum plasma level. It is narrower because it requires a solid immediate-release dosage form and oral administration.

A tradipitant tablet or capsule administered at 150 mg to 400 mg per day would fall within the literal scope of claim 4 if used to treat one of the claimed conditions.

How broad is the dose coverage?

The dose coverage is broad within the 150 mg-to-400 mg daily range. The dependent claims divide that range into commercially recognizable regimens:

Claim	Dose regimen
Claim 6	150-400 mg once daily
Claim 7	75-200 mg twice daily
Claim 8	85 mg twice daily or 100 mg twice daily

The twice-daily coverage in claim 7 mathematically reaches the same 150 mg-to-400 mg daily range as claim 4. Claim 8 then identifies 170 mg/day and 200 mg/day as specific regimens.

The patent therefore covers:

150 mg once daily;
170 mg once daily;
200 mg once daily;
300 mg once daily;
400 mg once daily;
75 mg twice daily;
85 mg twice daily;
100 mg twice daily; and
200 mg twice daily.

The claim language uses "about" for the 170 mg/day and concentration limitations. Courts generally interpret "about" in view of the specification, prosecution history, technical context, and evidence of ordinary meaning. It does not automatically create an unlimited range around the stated value.

What plasma concentrations are protected?

Claims 9 through 13 create a descending hierarchy of concentration requirements:

Claim	Minimum effective plasma concentration
Claim 9	Approximately 150 ng/mL or greater
Claim 11	Approximately 175 ng/mL or greater
Claim 12	Approximately 200 ng/mL or greater
Claim 13	Approximately 225 ng/mL or greater

Claim 10 adds a mechanistic limitation. It requires a disorder caused by over-expression of substance P or over-stimulation of the NK-1 receptor and ameliorated by tradipitant.

The concentration claims matter because a generic or follow-on sponsor may attempt to avoid a dose-specific claim by using a different dose. That strategy may fail if the alternative regimen still produces one of the claimed plasma concentrations and satisfies the remaining limitations.

The concentration claims also raise proof issues. A patentee would need to establish that the accused regimen achieves the claimed concentration in the relevant patient population or that the label and clinical instructions direct users toward that result. A generic sponsor could challenge infringement by showing that the product does not reliably produce the claimed exposure, although variability in pharmacokinetics may complicate that defense.

Which diseases and indications fall within the claims?

The patent lists a broad group of disorders rather than a single approved indication. The scope includes both symptoms and disease categories:

Category	Claimed conditions
Gastrointestinal	Nausea and vomiting
Dermatologic	Pruritus and atopic dermatitis
Neuropsychiatric	Anxiety and behavioral stressor
Addiction-related	Craving and substance dependence
Analgesic	Pain

This breadth increases potential value but also creates validity and infringement complexity. The claims are not limited to gastroparesis, although nausea and vomiting are central to tradipitant's clinical development. They also reach non-gastrointestinal uses that may require separate clinical evidence and regulatory strategies.

A product label that covers only one listed disorder could still implicate the patent. A product approved for an unlisted condition would not necessarily infringe unless the relevant use satisfies the claim language, including the disease limitation.

What is the patent term and expiration date?

Patent 10,772,880 was issued on September 15, 2020. Its patent term is generally determined by the earliest effective U.S. nonprovisional filing date or applicable international filing date, subject to patent-term adjustment, patent-term extension, terminal disclaimers, and other statutory adjustments.[1]

The patent's public bibliographic record identifies a 2015 priority context. On that basis, the nominal term is expected to extend into approximately 2036, before any adjustment. The exact enforceable expiration date must be taken from the USPTO Patent Center record and the patent's term-adjustment data.

Event	Date or status
Patent	U.S. 10,772,880
Issue date	September 15, 2020
Technology	Tradipitant dosing and plasma exposure
Patent type	Method-of-treatment
Expected nominal term	Approximately 2036, subject to statutory adjustments
Patent-term extension	No confirmed extension identified for this method patent
Orange Book status	No Orange Book listing identified because tradipitant is not an FDA-approved drug

A precise expiration date should not be equated with market exclusivity. FDA regulatory exclusivity, pediatric exclusivity, orphan-drug exclusivity, and patent-term adjustments can produce different end dates. In this case, the absence of FDA approval for tradipitant means the principal commercial barrier is the patent estate, clinical development status, and regulatory pathway rather than an existing Orange Book exclusivity period.

What is the FDA and Orange Book status of tradipitant?

Tradipitant is not an FDA-approved active ingredient. Vanda has studied tradipitant in clinical trials for gastroparesis, motion sickness, atopic dermatitis, and other conditions. The FDA issued a complete response letter concerning Vanda's gastroparesis application, and tradipitant has not obtained an approved U.S. label.[2][3]

Because there is no approved tradipitant drug product, the product is not expected to have an active Orange Book listing. Consequently:

There is no approved reference listed drug for a tradipitant ANDA;
There is no established Orange Book patent listing for tradipitant;
A conventional Paragraph IV certification pathway is not currently available for an unapproved reference product;
A future sponsor would likely need an NDA or another legally appropriate regulatory pathway unless an approved reference product is later established.

The absence of an Orange Book listing does not eliminate patent risk. A patent holder may enforce a method patent through a conventional infringement action if a commercial product and qualifying use exist.

How does Patent 10,772,880 affect Paragraph IV challenges?

A Paragraph IV challenge is generally tied to an ANDA referencing an FDA-approved listed drug and Orange Book-listed patents. Patent 10,772,880 does not presently operate as an Orange Book barrier because tradipitant lacks an approved reference product.

If tradipitant later receives approval, the patent holder could seek to list eligible patents in the Orange Book under FDA regulations. Whether this specific method patent would be listable would depend on the approved labeling, the product's dosage form, and the statutory requirements for drug-substance, drug-product, and method-of-use listings.[4]

If listed, a generic applicant could challenge the patent by:

Certifying that the patent is invalid;
Certifying that the patent is not infringed;
Submitting a section viii statement seeking approval only for non-patented uses; or
Waiting for patent expiration.

A section viii strategy could be difficult if the approved label includes the patented dosing regimen or directs use for one of the claimed conditions. A "skinny label" may reduce risk only if the carved-out label does not encourage the patented use.

What are the principal validity risks?

The patent's validity profile depends on the prior art, prosecution history, specification support, and the technical meaning of the dose and concentration limitations. The principal attack theories are as follows.

Obviousness

A challenger could argue that the claimed doses were obvious in view of earlier tradipitant clinical studies, pharmacokinetic data, dose-ranging studies, or prior NK-1 antagonist literature. The challenge would likely focus on whether a skilled person would have selected approximately 170 mg/day, 85 mg twice daily, or the claimed plasma thresholds with a reasonable expectation of success.

The patentee's strongest response would be evidence that the claimed exposure produced an unexpected therapeutic benefit or that earlier studies did not teach the claimed concentration target.

Written description and enablement

The disease list is broad. A challenger could argue that the specification does not adequately support treatment across all listed conditions or across the entire 150 mg-to-400 mg dose range. Enablement questions may also arise if the claims require achieving a concentration in diverse patient populations with materially different pharmacokinetic profiles.

The claims are more defensible where supported by clinical pharmacology data linking the dose to plasma exposure and therapeutic response.

Indefiniteness

Terms such as "about 170 mg/day," "about 175 ng/mL," "effective plasma concentration," and "for such time as required" could be challenged as indefinite if the specification and prosecution history do not provide objective boundaries.

The claim structure is less vulnerable where the specification reports assay methods, pharmacokinetic variability, target ranges, and accepted tolerances. "About" is commonly used in pharmaceutical claims, but its scope remains fact-specific.

Divided infringement and patient-administered treatment

Method-of-treatment claims can present divided-infringement issues. The relevant acts may be performed by different entities, including a manufacturer, prescriber, pharmacy, and patient. A product company may face direct or induced-infringement exposure depending on its label, promotional materials, distribution practices, and control over the regimen.

The risk is highest when a label expressly instructs 85 mg twice daily or another claimed regimen. It is lower when the product is distributed for an unclaimed indication and the sponsor does not encourage the claimed use.

What formulation protection does Patent 10,772,880 provide?

Patent 10,772,880 does not claim a specific excipient system, manufacturing process, particle size, polymorph, coating, capsule shell, or release technology.

Its formulation limitation is functional and structural at a high level:

Solid dosage form;
Immediate release;
Tradipitant; and
One or more pharmaceutically acceptable excipients.

Claim 5 identifies capsules and tablets. This is meaningful product coverage but not a narrow formulation patent. A competing manufacturer would likely be unable to avoid claim 4 merely by changing routine excipients if the product remains an oral solid immediate-release tradipitant dosage form administered within the claimed dose range.

A genuinely modified-release product might avoid the immediate-release limitation, but it could create other risks if the product still satisfies a concentration-based claim or is marketed for a claimed disorder.

What manufacturing and intellectual-property barriers remain?

The patent does not appear to create the principal manufacturing barrier. The main barriers are likely:

Clinical development and regulatory approval;
Access to tradipitant drug substance;
Know-how for solid oral formulation and bioavailability;
Clinical evidence supporting the claimed exposure;
Method-of-use patent risk; and
Freedom to operate around any separate compound, process, polymorph, or formulation patents.

Because tradipitant is an investigational molecule, supply-chain and development know-how may be more important than ordinary generic manufacturing economics. A competitor would also need to assess patents owned by Vanda, prior developers, licensors, and research collaborators covering the active compound, salts, crystalline forms, synthesis, formulations, and specific indications.

Which companies are challenging tradipitant patents?

No publicly established Paragraph IV litigation or approved generic challenge against Patent 10,772,880 has been identified. That result is consistent with tradipitant's unapproved status and the absence of an Orange Book reference product.

The competitive field is therefore composed primarily of:

Vanda Pharmaceuticals as the principal tradipitant developer;
Potential future NDA sponsors or licensees;
Generic drug companies that could pursue a future abbreviated pathway if an approved reference product emerges; and
Developers of competing antiemetic, NK-1 antagonist, gastroparesis, dermatology, and addiction therapies.

A future challenger would likely begin with a patent-validity and non-infringement analysis rather than a current Paragraph IV filing.

Are there licensing deals affecting Patent 10,772,880?

Tradipitant was originally associated with Eli Lilly's NK-1 research program before Vanda acquired rights to the molecule and related development assets. Vanda has been the principal public-facing developer of tradipitant in later clinical programs.[2]

The ownership and licensing chain for individual patents must be distinguished from the commercial development history. Patent 10,772,880 should be reviewed through USPTO assignment records for recorded assignments, security interests, or licenses. A development collaboration involving tradipitant does not automatically establish that every patent in the broader family is licensed on identical terms.

No publicly confirmed license has been identified that removes Vanda's ability to enforce this patent or grants a third party an exclusive right to commercialize a product covered by the claims.

How strong is the patent estate for tradipitant?

Patent 10,772,880 is a meaningful late-expiring method patent, but it is not a complete product monopoly.

Estate characteristic	Assessment
Chemical compound coverage	Not provided by this patent
Dose coverage	Broad from 150 mg to 400 mg/day
Exposure coverage	Stronger at 150, 175, 200, and 225 ng/mL thresholds
Formulation coverage	Limited to solid immediate-release products
Indication coverage	Broad list of nine disorders
Orange Book leverage	None identified while tradipitant remains unapproved
Generic litigation risk	Low in the current pre-approval setting; potentially material after approval
Validity exposure	Dose selection, pharmacokinetic predictability, written description, and indefiniteness
Design-around potential	Possible through indication, dose, release profile, or exposure strategy, subject to other patents

The estate's practical strength depends on whether a future commercial product uses the claimed oral dose and whether the sponsor's label includes one of the listed disorders. The patent is strongest against a conventional immediate-release tablet or capsule dosed at 85 mg twice daily for nausea, vomiting, or another claimed indication.

What generic launch scenarios exist for tradipitant?

Launch after patent expiration

A company could launch after the relevant patent expires, subject to FDA approval and any other unexpired patents or regulatory exclusivities.

Launch with a non-infringing indication

If an approved label excludes the patented disorders and does not encourage their use, a sponsor may reduce method-of-use risk. This approach would depend on the final labeling and actual marketing conduct.

Launch with a different dose

A dose outside 150 mg to 400 mg/day could avoid claims 4 through 8. It may still implicate claim 1 or claims 9 through 13 if the regimen produces the required plasma concentration and satisfies the disease limitation.

Launch with a different release profile

A modified-release product could avoid the solid immediate-release limitation in claim 4. It would not automatically avoid the concentration-based claims.

Litigation-based launch

A sponsor could challenge validity or non-infringement if a future regulatory pathway permits approval before patent expiration. The most material factual disputes would likely concern obviousness of the dose and exposure target, indefiniteness of "about," and whether the proposed label induces the claimed treatment method.

What geographic coverage does the patent provide?

Patent 10,772,880 provides rights only in the United States. International protection must be assessed separately through the related PCT application and national-phase filings.

A company evaluating global tradipitant commercialization should review:

European Patent Office family members;
Canadian and Australian counterparts;
Japanese and Korean filings;
Patent rights in major manufacturing jurisdictions;
National validity and lapse status;
Supplementary protection certificate prospects; and
Local rules governing Swiss-type or purpose-limited treatment claims.

A U.S. non-infringement position does not establish freedom to operate in Europe or other jurisdictions. The claim format, patent-term rules, and treatment-method exclusions differ materially by country.

Key Takeaways

U.S. Patent 10,772,880 is a method-of-treatment patent for tradipitant, not a compound patent.
Its core coverage includes 150 mg to 400 mg/day, including 85 mg twice daily and 100 mg twice daily.
Claims 1 and 9 through 13 add plasma-concentration thresholds from approximately 150 ng/mL to approximately 225 ng/mL.
The patent covers pain, nausea, vomiting, craving, substance dependence, anxiety, pruritus, atopic dermatitis, and related listed disorders.
Claim 4 is the principal product-use claim for oral solid immediate-release tablets and capsules.
Tradipitant has not received FDA approval, and no active Orange Book listing or Paragraph IV challenge has been identified.
The nominal patent term is expected to extend into approximately 2036, subject to USPTO term-adjustment data and any terminal disclaimer or other statutory modification.
The strongest infringement case would involve an immediate-release oral product labeled for a claimed disorder at 85 mg twice daily or another claimed dose.
The principal validity issues are obviousness of the dose and exposure targets, written description, enablement, and the boundaries of "about" and "effective plasma concentration."
A full freedom-to-operate review must include separate compound, formulation, polymorph, synthesis, manufacturing, and international patent families.

FAQs About U.S. Patent 10,772,880 and Tradipitant

Does Patent 10,772,880 claim tradipitant itself?

No. The patent claims methods of administering tradipitant at specified doses and plasma concentrations. Separate patents would be needed to protect the chemical compound, salts, polymorphs, synthesis, or formulation technology.

Can a tradipitant product at 100 mg twice daily infringe?

Yes. Claim 8 expressly recites 100 mg twice daily. Claims 4 and 7 also cover a 200 mg/day regimen if the product is an oral solid immediate-release form used for a claimed disorder.

Does a non-oral tradipitant product avoid the patent?

It may avoid claims requiring oral administration or an oral solid immediate-release form. It could still implicate claim 1 or the concentration claims if all limitations, including the disease and exposure requirements, are satisfied.

Would FDA approval automatically create Orange Book protection?

No. FDA approval alone does not guarantee listing. The patent must satisfy Orange Book listing requirements and correspond to the approved drug product or method of use. Tradipitant currently lacks an approved U.S. reference product.

Could a generic avoid the patent by using 140 mg/day?

A 140 mg/day regimen would fall outside the express 150 mg-to-400 mg/day range in claim 4 and the specified twice-daily ranges in claims 7 and 8. It could still face exposure-based risk if it achieves a claimed plasma concentration and meets the other limitations of claims 1 or 9 through 13.

References

United States Patent and Trademark Office. (2020). U.S. Patent No. 10,772,880, Methods of treating diseases with tradipitant. https://patents.google.com/patent/US10772880B2/en
Vanda Pharmaceuticals Inc. (2023). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. U.S. Securities and Exchange Commission. https://www.sec.gov/
U.S. Food and Drug Administration. (2020). FDA complete response letter and regulatory information concerning tradipitant. https://www.fda.gov/
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, commonly known as the Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files-sources-and-availability

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Vanda Pharms Inc	NEREUS	tradipitant	CAPSULE;ORAL	220152-001	Dec 30, 2025		RX	Yes	Yes	⤷ Start Trial	⤷ Start Trial				PREVENTION OF VOMITING INDUCED BY MOTION IN ADULTS BY ADMINISTERING TRADIPITANT	⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2016226006	⤷ Start Trial
Australia	2021202956	⤷ Start Trial
Australia	2023233141	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Summary for Patent: 10,772,880